TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10993855

Group type: EXPERIMENTAL
Intervention: US intervention (angiography and revascularization)
Number of subjects: 3172

Group type: COMPARATOR
Intervention: Canadian intervention (noninvasive stress testing)
Number of subjects: 3172
Study: 9065253

Group type: EXPERIMENTAL
Intervention: ICUs with more than 600 beds
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Peripheral venous catheters
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Catheterisation of the urinary tract
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Central venous catheters
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Gastric tubes
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Artificial ventilation
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Routine microbiological surveillance of tracheal aspirates
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Routine microbiological surveillance of urine
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Daily changing of ventilation tubes
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Infusion sets changed daily
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Drugs for the prevention of stress ulcers
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Sucralfate for stress ulcer prevention
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract
Number of subjects: 515
Study: 2003537

Group type: EXPERIMENTAL
Intervention: Educational preterm delivery prevention program
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Educational program + Home uterine monitoring
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group (similar high-risk patients who did not participate in these programs)
Number of subjects: 394
Study: 6148312

Group type: EXPERIMENTAL
Intervention: Bopindolol (1-4 mg once daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propranolol (40-120 mg t.i.d.)
Number of subjects: 17
Study: 28082277

Group type: EXPERIMENTAL
Intervention: Collaborative medical and chiropractic care with interprofessional education, clinical record exchange, and team‐based case management
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concurrent medical and chiropractic care
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 19
Study: 27644138

Group type: EXPERIMENTAL
Intervention: ε-caprolactam concentration of 0.05 mg/m³
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ε-caprolactam concentration of 0.5 mg/m³
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ε-caprolactam concentration of 5.0 mg/m³
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control condition (0.0 mg/m³)
Number of subjects: 52
Study: 25008901

Group type: EXPERIMENTAL
Intervention: Early booster (9 to 12 months)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Late booster (15 to 18 months)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Catch-up vaccination (2 doses plus experimental booster)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Serious adverse events in early booster group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Serious adverse events in catch-up group
Number of subjects: 256
Study: 22181026

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT)
Number of subjects: 10
Study: 20044704

Group type: EXPERIMENTAL
Intervention: Exergaming group (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 19123874

Group type: EXPERIMENTAL
Intervention: Shirodhara treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control position
Number of subjects: 32
Study: 15927409

Group type: EXPERIMENTAL
Intervention: Immediate concurrent chemoradiation (cisplatin-based) with short overall treatment time (completed within 5 days of plan)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Immediate concurrent chemoradiation (cisplatin-based) with prolonged treatment time (protocol violation)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Treatment time as a continuous variable
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Immediate concurrent chemoradiation (cisplatin-based)
Number of subjects: 474
Study: 15478385

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 2000 microg/d via a 750-mL primed spacer for 2 weeks
Number of subjects: 20
Study: 11506515

Group type: EXPERIMENTAL
Intervention: Dacron grafts
Number of subjects: 194

Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 194
Study: 9247510

Group type: COMPARATOR
Intervention: 400 IU of vitamin E, 500 mg of vitamin C, 12 mg of beta-carotene (mid-dose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin E, 1,000 mg of vitamin C, 24 mg of beta-carotene (high dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 45
Study: 8391566

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bottle-weight measure
Number of subjects: 41

Group type: COMPARATOR
Intervention: Urine bioassay
Number of subjects: 41

Group type: COMPARATOR
Intervention: Parent report diary
Number of subjects: 41
Study: 3552460

Group type: EXPERIMENTAL
Intervention: 10/10/10 micrograms HA formulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Monovalent A/Singapore/6/86-like vaccine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Trivalent A/Mississippi, A/Chile, B/Ann Arbor influenza vaccine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: A/Singapore vaccine
Number of subjects: 120
Study: 29436348

Group type: EXPERIMENTAL
Intervention: Stored food samples
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Flies captured in households
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Paired fly-food samples
Number of subjects: 182
Study: 27840374

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (LA) treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 100
Study: 24411718

Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids (1.14g DHA and 1.56g EPA)
Number of subjects: 20
Study: 24152081

Group type: EXPERIMENTAL
Intervention: Parent-Led Activity and Nutrition for Healthy Living weight management program (10-week duration, including two motivational interviewing visits, four group sessions, and four phone follow-ups)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study: 20846018

Group type: EXPERIMENTAL
Intervention: Tailored cardiac rehabilitation program with motivational interviewing guided by the Transtheoretical Model (TTM)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 225
Study: 18553032

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% (15 ml)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ropivacaine 0.0625% plus 75 microg clonidine (15 ml)
Number of subjects: 32
Study: 16651056

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (mean INR 1.4, goal INR <2.0)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Alcohol intake categories (non-, light, moderate, heavier drinkers)
Number of subjects: 1244
Study: 12816770

Group type: COMPARATOR
Intervention: L-MUFA (7.8% of energy from MUFAs)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: M-MUFA (10.3% of energy from MUFAs)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: H-MUFA (13.7% of energy from MUFAs)
Number of subjects: 35
Study: 10853566

Group type: EXPERIMENTAL
Intervention: Bupivacaine administered preoperatively
Number of subjects: 0
Study: 7756096

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily for 8 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lorazepam 2 mg single dose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2312774

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK 100-200 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 156006

Group type: EXPERIMENTAL
Intervention: Grading system for acne severity on a zero to eight scale anchored to photographic standards.
Number of subjects: 0
Study: 30346364

Group type: EXPERIMENTAL
Intervention: Study invitation placed early within discharge instructions (DCIs)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Laceration diagnosis
Number of subjects: 963

Group type: COMPARATOR
Intervention: Parents of Hispanic children
Number of subjects: 963
Study: 31989459

Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10% dextrose solution
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 45
Study: 29390915

Group type: EXPERIMENTAL
Intervention: Infusion site failure detection algorithm
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) arm
Number of subjects: 19
Study: 27444763

Group type: EXPERIMENTAL
Intervention: Paracervical local anesthesia combined with sedation (group LA + S; n = 76)
Number of subjects: 153

Group type: COMPARATOR
Intervention: General anesthesia (group GA; n = 77)
Number of subjects: 153
Study: 23987833

Group type: EXPERIMENTAL
Intervention: Trabectedin as second-line treatment (24-hour infusion every 3 weeks)
Number of subjects: 129
Study: 22534669

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Gefitinib (250 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Pemetrexed (500 mg/m²)
Number of subjects: 70
Study: 20126965

Group type: EXPERIMENTAL
Intervention: Resistance Trained Creatine (RTCr, 5g Cr)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance Trained Protein (RTPr, 35g whey Pr)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance Trained Creatine and Protein (RTCrPr, 5g Cr and 35g Pr)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Resistance Trained Placebo (RTP)
Number of subjects: 42
Study: 18082920

Group type: EXPERIMENTAL
Intervention: Cycling at two different cadences
Number of subjects: 20
Study: 15671124

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg on days 1-8, 40 mg on days 8-15)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg on days 1-8, 100 mg on days 8-15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12952837

Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 21
Study: 10494365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metoclopramide (0.3 mg x kg‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dimenhydrinate (1 mg x kg‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Combination of dimenhydrinate (1 mg x kg‐1) and metoclopramide (0.3 mg x kg‐1)
Number of subjects: 120
Study: 9005795

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg once a day for medium urinary tract infections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ofloxacin 100 mg twice a day for 3 to 7 days for severe lower urinary tract infections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg twice a day for 7 to 10 days for severe upper urinary tract infections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ofloxacin 50 mg once a day for 6 months for frequent acute recurring infections
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ofloxacin (various regimens)
Number of subjects: 30
Study: 2073484

Group type: EXPERIMENTAL
Intervention: 1.1% lidocaine hydrocarbonate (CO2) with 1:200,000 epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1.0% lidocaine hydrochloride (HCl) with 1:200,000 epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: lidocaine HCl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: lidocaine CO2
Number of subjects: 50
Study: 6788406

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily, orally)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (inhalation of 20 mg, four times daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 64
Study: 6366148

Group type: EXPERIMENTAL
Intervention: Four-drug program (cyclophosphamide, vincristine, methotrexate, prednisone [COMP])
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 10-drug program (LSA2-L2 modified)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: COMP
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: LSA2-L2
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall (both treatments)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall (adverse events)
Number of subjects: 73
Study: 30589654

Group type: EXPERIMENTAL
Intervention: Slow Training (ST) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional Training (TT) group
Number of subjects: 40
Study: 28916891

Group type: EXPERIMENTAL
Intervention: Loop-tip guidewire (LGW)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Straight-tip guidewire (SGW)
Number of subjects: 192
Study: 27399527

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 24646343

Group type: EXPERIMENTAL
Intervention: SMS group (n=56)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Non-SMS group (n=48)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (n=57)
Number of subjects: 161
Study: 22975616

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (5 cycles of fluorouracil and leucovorin)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chemoradiation therapy (1 cycle of FL, then 45 Gy radiation concurrently with 2 cycles of FL, followed by 2 cycles of FL)
Number of subjects: 90
Study: 19460762

Group type: EXPERIMENTAL
Intervention: Comfrey root extract ointment (4 g per application, three times a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo ointment (4 g per application, three times a day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comfrey root extract ointment
Number of subjects: 120
Study: 17914338

Group type: EXPERIMENTAL
Intervention: Informed consent discussion with illustrated flip chart
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care consent process (without flip chart)
Number of subjects: 122
Study: 16037704

Group type: EXPERIMENTAL
Intervention: Midnight removal of catheter (ROC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Early morning removal of catheter (ROC)
Number of subjects: 84
Study: 12025737

Group type: EXPERIMENTAL
Intervention: Photic stimulation (PS)
Number of subjects: 0
Study: 10025472

Group type: EXPERIMENTAL
Intervention: Vitamin E (100 mg daily) and Vitamin C (500 mg daily) for 15 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7789200

Group type: EXPERIMENTAL
Intervention: Sociometrically neglected children
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Aggressive-rejected children
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Submissive-rejected children
Number of subjects: 423

Group type: COMPARATOR
Intervention: Average status children
Number of subjects: 423
Study: 2347518

Group type: EXPERIMENTAL
Intervention: Aspirin at very ultra low dosage
Number of subjects: 20
Study: 373517

Group type: EXPERIMENTAL
Intervention: Nebulized atropine sulfate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of nebulized atropine sulfate and isoproterenol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Isoproterenol alone
Number of subjects: 13
Study: 31242065

Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 31209815

Group type: EXPERIMENTAL
Intervention: PPOS protocol
Number of subjects: 157

Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 157
Study: 27623133

Group type: EXPERIMENTAL
Intervention: SIMV + VG
Number of subjects: 34

Group type: COMPARATOR
Intervention: PSV + VG
Number of subjects: 34
Study: 25746779

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography
Number of subjects: 18840

Group type: COMPARATOR
Intervention: Single-view chest radiography
Number of subjects: 18840

Group type: EXPERIMENTAL
Intervention: False positive screening results
Number of subjects: 18840
Study: 23904337

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (0.1 mg/kg, n = 234)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Intrarectal diazepam (0.5 mg/kg, n = 202)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam
Number of subjects: 436

Group type: COMPARATOR
Intervention: Intrarectal diazepam
Number of subjects: 436
Study: 21903893

Group type: EXPERIMENTAL
Intervention: Armodafinil (titrated to 250 mg daily in the morning)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Quetiapine alone
Number of subjects: 37
Study: 19221726

Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg, 3 times a day for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17591036

Group type: EXPERIMENTAL
Intervention: Probiotics (Enterococcus faecalis T‐110, Clostridium butyricum TO‐A, and Bacillus mesentericus TO‐A) administered perioperatively, starting immediately after admission, 3 to 15 days before the operation, and continued until hospital discharge.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 70
Study: 15040824

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D Program (1000 mg of elemental calcium as calcium carbonate and 400 IU of vitamin D3 daily)
Number of subjects: 9605

Group type: COMPARATOR
Intervention: Environmental and Health Program (evaluation and suggestions for improvement of the domestic environment)
Number of subjects: 9605
Study: 10632537

Group type: EXPERIMENTAL
Intervention: 4 mg of styrene maleic acid neocarzinostatin in 4 ml of Lipiodol (Group A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 100 mg of epirubicin in 4 ml of Lipiodol (Group B)
Number of subjects: 37
Study: 11517475

Group type: EXPERIMENTAL
Intervention: Patients with ischemic disorders of cerebral circulation
Number of subjects: 45
Study: 8211540

Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg oral)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ceftriaxone (250 mg intramuscular)
Number of subjects: 59
Study: 3546170

Group type: EXPERIMENTAL
Intervention: Non-living promastigote vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31682572

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) blended with weekly real-time therapist chat sessions for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minimal attention control
Number of subjects: 70
Study: 27942857

Group type: EXPERIMENTAL
Intervention: Individualized 3-week exercise program with two additional 1-week inpatient stays after 4 and 8 months
Number of subjects: 194

Group type: COMPARATOR
Intervention: 3-week rehabilitation program without follow-up care
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 194
Study: 25683748

Group type: EXPERIMENTAL
Intervention: High-nitrate (HN) diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 19
Study: 23808298

Group type: EXPERIMENTAL
Intervention: Ivabradine (dose titrated during 2 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination therapy with ivabradine + atenolol (in half doses)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ivabradine (15 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Atenolol (control group)
Number of subjects: 31
Study: 21861038

Group type: EXPERIMENTAL
Intervention: Transition to low-molecular-weight heparin (LMWH) - enoxaparin: 1 mg/kg 2x/day before ablation, and 0.5 mg/kg 2x/day after ablation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Maintenance of warfarin with therapeutic INR (between 2.0 and 3.0)
Number of subjects: 140
Study: 18444883

Group type: EXPERIMENTAL
Intervention: VCL‐CB01 vaccine (1- or 5-mg doses) administered on a 0-, 2-, and 8-week schedule
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: VCL‐CB01 vaccine (5-mg doses) administered on a 0-, 3-, 7-, and 28-day schedule
Number of subjects: 44
Study: 16935602

Group type: EXPERIMENTAL
Intervention: Tungsten powder balloon
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mercury-containing device
Number of subjects: 24
Study: 12963561

Group type: EXPERIMENTAL
Intervention: EX + WL
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: EX only
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study: 11269896

Group type: EXPERIMENTAL
Intervention: Local conjunctival immunotherapy (LCIT) with standardized dermatophagoides pteronyssinus (Dp) extracts, administered daily for 6 months at increasing concentrations starting from 10 AU/ml to a maintenance dose of 1,000 AU/ml.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment, administered daily for 6 months.
Number of subjects: 24
Study: 9109894

Group type: EXPERIMENTAL
Intervention: 16 mg/d tiagabine
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 32 mg/d tiagabine
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 56 mg/d tiagabine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 8239351

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 3084705

Group type: EXPERIMENTAL
Intervention: Multiple-monitored electroconvulsive therapy (MMECT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional electroconvulsive therapy (CECT)
Number of subjects: 54